Tracked deals
9
9 tracked deals across 2026.
Tracked deals
9
9 tracked deals across 2026.
Buyer mix
PE-led
6 pe · 2 strategic
Top trend
Volume peaked in 2025
13 tracked deals announced in 2025.
Buyer Snapshot
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Apollo Global Management (funds managed by) | 1 | Alternative investment manager making private capital inv... | PE |
| Boston Scientific Corporation | 1 | Global medical technology company focused on cardiovascul... | Strategic |
| Catalio Capital Management | 1 | Investment firm investing across healthcare private, publ... | PE |
| Greyhill Ventures Oral Care Fund I LP | 1 | Early-stage investment fund focused on technology compani... | PE |
| Kedaara Capital | 1 | Operationally oriented private equity firm investing in c... | PE |
| OrbiMed | 1 | Healthcare investment firm providing equity and credit fi... | PE |
| Plaza Capital | 1 | Toronto-based boutique investment firm focused on the Can... | PE |
| Stephen Industries Inc Oy | 1 | Closely associated investor subscribing to Bioretec Oy sh... | Mixed |
| Stryker | 1 | Global medical technology company operating across MedSur... | Strategic |
Last 8 years
Supporting Data
Stryker agreed to invest approximately $400 million in CMR Surgical through preferred equity, with an exclusive option to acquire the company’s remaining equity in the future. The strategic alliance also makes Stryker the exclusive U.S. sales agent for CMR’s Versius portfolio, while CMR retains product development and commercialization outside the United States.
AVAVA secured a $45 million financing package comprising a $15 million debt facility and a $30 million equity financing, with Catalio Capital Management leading both. New and existing investors also participated; AVAVA plans to use the proceeds for commercial expansion, its innovation pipeline, and global growth.
Greyhill Ventures Oral Care Fund I LP made an equity investment in Oratray, a developer of prefilled dental tray drug/device delivery products. The investment closed in March 2026; its amount was not disclosed. The capital supports Oratray’s platform development, including its fluoride tray advancing through the FDA 510(k) pathway.
Kedaara Capital announced a USD 200 million strategic investment in Tynor Orthotics Private Limited, an Indian orthopaedic supports, mobility aids, and rehabilitation brand. The investment is intended to help deepen Tynor’s orthopaedic-focused wellness platform, expand reach in India and international markets, and support manufacturing and growth initiatives alongside promoters, management, and strategic partner Thuasne.
Spring Loaded Technology, a Canadian orthopedic bracing and mobility solutions company, announced a strategic investment from Plaza Capital to support its next phase of growth. The funding is intended to accelerate international expansion (including the United States and Europe), further R&D, and continued advancement of evidence-based mobility solutions.
Boston Scientific Corporation invested $1.5 billion for an approximately 34% equity stake in privately held MiRus LLC. Under the investment agreement, Boston Scientific received an exclusive option to acquire MiRus’s SIEGEL balloon-expandable TAVR system business for up to $3 billion in additional cash payments, subject to clinical and regulatory milestones and closing conditions.
vVARDIS Holding AG announced a strategic minority investment from funds managed by Apollo Global Management to support the company’s global expansion. The funding is intended to accelerate the commercial rollout of vVARDIS’ non-invasive Curodont peptide-based dental treatment, with a focus on scaling adoption across the United States and Europe.
Bioretec Oy disclosed managers’ transaction activity indicating that Stephen Industries Inc Oy, a closely associated party of board member Kustaa Poutiainen, subscribed for shares outside a trading venue. The transaction details were reported with an aggregated share volume and very low nominal prices per unit.
Thrombolex, Inc., a commercial-stage medical device company focused on pharmaco-mechanical lysis for thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed. The funding is intended to expand U.S. commercialization and advance clinical evidence generation for its FDA-cleared BASHIR Endovascular Catheter (BEC) platform for pulmonary embolism and other VTE indications.
Full Export
Get the full acquisitions list for this page as CSV + XLSX.
Find buyers actively acquiring medical devices companies.